Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Clin Pathol. 2013 Aug;140(2):225-30. doi: 10.1309/AJCP4MXTNQRVOE2T.

HepPar-1 expression in primary lung adenocarcinoma.

Author information

  • 1Department of Pathology, UPMC Presbyterian Shadyside, Presbyterian Campus-A610, 200 Lothrop St, Pittsburgh, PA 15213-2582, USA. yousemsa@upmc.edu

Abstract

OBJECTIVES:

To study a subset of lung adenocarcinomas with aberrant HepPar-1 antigen expression.

METHODS:

We performed a clinicopathologic review of 16 cases.

RESULTS:

Of 241 primary lung adenocarcinomas tested for expression of the HepPar-1 antigen, 16 (6.6%) were positive. The cases occurred in older smokers with an equal sex distribution. Morphologically, these pulmonary adenocarcinomas had an acinar-predominant architecture, and prominent cribriform growth, with HepPar-1-expressing tumor cells being uniformly columnar with abundant bipolar lightly eosinophilic cytoplasm. HepPar-1 was coexpressed with thyroid transcription factor 1 in 94% of cases. No EGFR mutations were identified, while 31% of cases were positive for KRAS codon 12 mutations.

CONCLUSIONS:

Although aberrant HepPar-1 expression was frequently seen in tumors with visceral pleural and angiolymphatic invasion, its prognostic significance is uncertain.

KEYWORDS:

Adenocarcinoma; HepPar-1 antigen; Lung

PMID:
23897259
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk